Background The introduction of rituximab (R) to conventional CHOP chemotherapy for newly
diagnosed diffuse large B-cell lymphoma (DLBCL) led to an unequivocal improvement in …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with variable outcomes.
Despite the majority of patients being cured with combination chemoimmunotherapy, up to …

Paraquat (PQ) as a herbicide and an environmental pollutant with increasing importance
due to its toxicity to humans and animals. This study aimed to evaluate the protective and …

Despite the use of modern immunochemotherapy regimens, almost 50% of patients with
diffuse large-B-cell lymphoma will relapse. Current prognostic models, including the …

Background Recent research has shown a correlation between immune microenvironment
and lymphoma biology. This study aims to investigate the prognostic significance of the …

Purpose: Patients with metastatic or relapsed pediatric sarcomas receive cytotoxic regimens
that induce high remission rates associated with profound lymphocyte depletion, but …

The neutrophil/lymphocyte (N/L) ratio at diagnosis has been shown to be a prognostic factor
for survival in solid tumors. The N/L ratio at diagnosis as a prognostic factor for non-Hodgkin …

The prognostic value of absolute lymphocytic count (ALC), has been a recent matter of
debate in non-Hodgkin-lymphoma (NHL). We assessed prospectively the value of ALC at …

Objectives: To evaluate the prognostic value of absolute lymphocyte count (ALC) at
diagnosis in patients with diffuse large B‐cell lymphoma (DLBCL). Methods: In a large …

Aim To determine the prognostic value of baseline red blood cell distribution width (RDW) in
diffuse large B cell lymphoma (DLBCL) patients. Methods Data from 81 DLBCL patients …